Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 11, Number 10—October 2005
Research

Methicillin-resistant Staphylococcus aureus and Vancomycin-resistant Enterococci Co-colonization1

Jon P. Furuno*Comments to Author , Eli N. Perencevich*†‡, Judith A. Johnson*†, Marc-Oliver Wright‡2, Jessina C. McGregor*, J. Glenn Morris*†, Sandra M. Strauss*, Mary-Claire Roghman*†, Lucia L. Nemoy*†, Harold C. Standiford‡, Joan N. Hebden‡, and Anthony D. Harris*†‡
Author affiliations: *University of Maryland School of Medicine, Baltimore, Maryland, USA; †Veterans' Affairs Maryland Health Care System, Baltimore, Maryland, USA; ‡University of Maryland Medical Center, Baltimore, Maryland, USA

Main Article

Table 1

Characteristics of the study population by co-colonization status*

Characteristic MRSA/VRE co-colonization (n = 65) No co-colonization (n = 2,375) p value
Demographic variable
Mean age, y (SD) 61.1 (15.1) 55.7 (16.0) <0.01
Male sex, n (%) 43 (66.2) 1,277 (53.8) 0.05
Variables from current admission
Type of ICU (MICU), n (%) 49 (75.4) 1,014 (42.7) <0.01
Transfer from another hospital, n (%) 10 (15.4) 711 (29.9) <0.01
Comorbidities
HIV/AIDS, n (%) 3 (4.6) 77 (3.2) 0.54
Malignancy, n (%) 6 (9.2) 423 (17.8) 0.07
Cardiac disease, n (%) 20 (30.8) 486 (20.5) 0.04
Diabetes mellitus, n (%) 14 (21.5) 486 (20.5) 0.83
Liver disease, n (%) 2 (3.1) 182 (7.7) 0.17
Renal disease, n (%) 3 (4.6) 74 (3.1) 0.50
Mean Charlson comorbidity score (SD) 2.1 (2.2) 2.3 (2.3) 0.37
Antimicrobial drugs before culture
Vancomycin, n (%) 14 (21.5) 226 (9.5) <0.01
Piperacillin-tazobactam, n (%) 17 (26.2) 398 (16.8) 0.05
Imipenem, n (%) 2 (3.1) 72 (3.0) 0.98
Cephalosporins, n (%) 7 (10.8) 426 (17.9) 0.14
Aminoglycosides, n (%) 4 (6.2) 109 (4.6) 0.55
Fluoroquinolones, n (%) 11 (16.9) 223 (9.4) 0.04
Variables from previous admissions
Previous MRSA colonization/infection 31 (47.7) 145 (6.1) <0.01
Previous VRE colonization/infection 18 (27.7) 178 (7.5) <0.01
Hospital admission (<1 y), n (%) 37 (57.9) 751 (31.6) <0.01
ICU admission (<1 y), n (%) 17 (26.2) 309 (13.0) <0.01
Antimicrobial drugs during admission (<1 y), n (%) 33 (50.8) 606 (25.5) <0.01

*MRSA, methicillin-resistant Staphylococcus aureus; VRE, vancomycin-resistant enterococci; SD, standard deviation; ICU, intensive care unit; MICU, medical ICU.

Main Article

1These data were presented in part at the 44th Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington DC, September 2004.

2Current affiliation: Marshfield Clinic Research Foundation, Marshfield, Wisconsin, USA.

Page created: February 22, 2012
Page updated: February 22, 2012
Page reviewed: February 22, 2012
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external